Literature DB >> 25251832

HIV and the spectrum of human disease.

Sebastian Lucas1, Ann Marie Nelson.   

Abstract

Infection with the human immunodeficiency virus (HIV) causes systemic T cell destruction and reduced cell-mediated immunity that leads to a wide range of opportunistic infections and cancers. Second, it directly damages many tissues - gut, brain, lung - through mononuclear cell infection and activation. Third, through immune activation and effects on endothelia, it can cause more subtle systemic organ damage, such as chronic cardiovascular, hepatic, pulmonary and central nervous system disease. Antiretroviral treatment has enabled HIV-infected persons to live with chronic infection, although with some side-effects and mortality, including reactions due to the immune reconstitution inflammatory syndrome (IRIS). As cohorts of infected people get older, age-related diseases will combine with chronic HIV infection to produce disabilities whose scale is not yet understood. HIV is detectable in tissues by immunohistochemistry when infection loads are high, such as at first presentation. Pathologists should proactively consider HIV disease in routine diagnostic work, so as to identify more HIV-infected patients and enable their optimal management.
Copyright © 2014 Pathological Society of Great Britain and Ireland. Published by John Wiley & Sons, Ltd.

Entities:  

Keywords:  AIDS; HIV; HIVp24; IRIS; immune activation; pathology; review

Mesh:

Substances:

Year:  2015        PMID: 25251832     DOI: 10.1002/path.4449

Source DB:  PubMed          Journal:  J Pathol        ISSN: 0022-3417            Impact factor:   7.996


  34 in total

Review 1.  Pathology of infectious diseases: what does the future hold?

Authors:  Paul Hofman; Sebastian Lucas; Grégory Jouvion; Arnault Tauziède-Espariat; Fabrice Chrétien; Gieri Cathomas
Journal:  Virchows Arch       Date:  2017-02-10       Impact factor: 4.064

2.  Tissue is the issue: how altruistic people with HIV are changing the HIV tissue reservoir landscape.

Authors:  Stephen A Rawlings; Sara Gianella
Journal:  Future Virol       Date:  2020-08-03       Impact factor: 1.831

3.  The Selective Serotonin Reuptake Inhibitor Citalopram Decreases Human Immunodeficiency Virus Receptor and Coreceptor Expression in Immune Cells.

Authors:  Jeffrey M Greeson; David R Gettes; Sergei Spitsin; Benoit Dubé; Tami D Benton; Kevin G Lynch; Steven D Douglas; Dwight L Evans
Journal:  Biol Psychiatry       Date:  2015-11-10       Impact factor: 13.382

Review 4.  The Immune Fulcrum: Regulatory T Cells Tip the Balance Between Pro- and Anti-inflammatory Outcomes upon Infection.

Authors:  Laura E Richert-Spuhler; Jennifer M Lund
Journal:  Prog Mol Biol Transl Sci       Date:  2015-08-18       Impact factor: 3.622

5.  Risk factors for esophageal cancer in a high-incidence area of Malawi.

Authors:  Anja L Geßner; Angelika Borkowetz; Torsten J Wilhelm; Enock Ludzu; Michael Baier; Yamikani Mastala; Saulos Nyirenda; Henning Mothes
Journal:  Cancer Causes Control       Date:  2021-08-03       Impact factor: 2.506

6.  Nucleoside Reverse Transcriptase Inhibitor Interaction with Human Equilibrative Nucleoside Transporters 1 and 2.

Authors:  Siennah R Miller; Raymond K Hau; Joseph L Jilek; Mark N Morales; Stephen H Wright; Nathan J Cherrington
Journal:  Drug Metab Dispos       Date:  2020-05-11       Impact factor: 3.922

7.  The Extended Impact of Human Immunodeficiency Virus/AIDS Research.

Authors:  Tara A Schwetz; Anthony S Fauci
Journal:  J Infect Dis       Date:  2019-01-01       Impact factor: 5.226

Review 8.  Avoiding Drug Resistance in HIV Reverse Transcriptase.

Authors:  Maria E Cilento; Karen A Kirby; Stefan G Sarafianos
Journal:  Chem Rev       Date:  2021-01-28       Impact factor: 60.622

9.  Predicting Drug Interactions with Human Equilibrative Nucleoside Transporters 1 and 2 Using Functional Knockout Cell Lines and Bayesian Modeling.

Authors:  Siennah R Miller; Xiaohong Zhang; Raymond K Hau; Joseph L Jilek; Erin Q Jennings; James J Galligan; Daniel H Foil; Kimberley M Zorn; Sean Ekins; Stephen H Wright; Nathan J Cherrington
Journal:  Mol Pharmacol       Date:  2020-12-01       Impact factor: 4.436

10.  Fatal Infections Among Cancer Patients: A Population-Based Study in the United States.

Authors:  Yongqiang Zheng; Ying Chen; Kaixu Yu; Yun Yang; Xindi Wang; Xue Yang; Jiaxin Qian; Ze-Xian Liu; Bian Wu
Journal:  Infect Dis Ther       Date:  2021-03-24
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.